Thanks to its selección for a Ministry of Trade, Industry and Energy proyecto, RudaCure Inc. was able to receive apoyo for raw material pharmaceutical producción and formulación investigación for RCI001. Además, by being seleccionada for the SME Innovación Growth proyecto, la empresa became able to conduct nacional e internacional ensayo clínicos.
RCI001, which ha sido attracting attention as a candidato substance for tratamiento de la enfermedad de ojo seco, demonstrates antiinflamatorio effects by selectively modulating multifunctional signaling molecules. It también being developed as an eye drop due to its observed improvement in secreción lagrimal function. This new candidato a fármaco is targeting ensayo clínico entry nacionalally and internacionally el próximo año.
